OBJECTIVES The second-generation Jenavalve prosthesis (Jenavalve Technology, Inc., Munich, Germany) is the first transcatheter valve Conformité Européene (CE) marked for treatment of both aortic stenosis (AS) and pure aortic regurgitation (AR). Although the feasibility of the Jenavalve transcatheter aortic valve implantation (TAVI) in patients with pure AR has been described, haemodynamic and f...

A 81-year woman was admitted to our institution due to worsening chronic heart failure. The patient presented herself with severe aortic valve stenosis and mitral valve insufficiency. Due to estimated high operative risk a TAVI approach was chosen. Following the fist TAVI implantation (Sapien XT 26 mm) a big paravalvular leakage was diagnosed. Hence, in order to close the paravalular leakage, a...

Prosthesis-patient Mismatch (PPM) is not uncommon with an incidence reported up to 70% after aortic valve (AV) replacement. Severe forms of PPM are less common (up to 20%); PPM can lead to increased short- and long-term morbidity and mortality. It is important to discriminate PPM from other forms of prosthetic valve dysfunction. Sometimes, prosthetic valve degenerative disease may coexist with ...

BACKGROUND A new generation of balloon-expandable valves (e.g. Edwards SAPIEN XT) enables the use of a decreased sheath size using the NovaFlex™ delivery system for transfemoral transcatheter aortic valve implantation (TAVI). However, there are few data analysing the efficacy and safety of this new prosthesis. AIMS To evaluate periprocedural and 30-day clinical outcomes using the Edwards SAPI...

An 80-year-old woman was admitted to our institution because of shortness of breath (New York Heart Association grade III) and stable angina pectoris (Canadian Cardiovascular Society [CCS] grade II). Two years ago, the patient had a posterior wall infarction successfully treated by percutaneous coronary intervention and stent implantation. A low-gradient aortic stenosis with an aortic valve are...

previously undergone bio-prosthetic aortic valve implantation in 2004 for aortic stenosis. When he re-presented with heart failure in 2012 due to re-stenosis of the aortic valve bio-prosthesis, he was deemed not suitable for re-do surgery because of high-risk involved. Thus, he had TAVI using Medtronic CoreValve. Three-dimensional transoesophageal echocardiogram (3D TEE) and multi-slice contras...

Transcatheter aortic valve implantation was developed to offer a therapeutic solution to patients with severe symptomatic aortic stenosis who are not candidates for conventional aortic valve replacement. The improvement in transcatheter aortic valve implantation outcomes is still of concern in the areas of stroke, vascular injury, heart block, paravalvular regurgitation and valve durability. Co...

Abstract A 63–year–old male patient with a mechanical mitral prosthesis and permanent atrial fibrillation in TAO was hospitalized for heart failure during SARS CoV–2 infection April 2022; the transthoracic echocardiogram performed hospitalization showed an ejection fraction of 38% The rehospitalized September 2022 due to worsening general conditions suspected pneumonia. complicated by brady AF ...

Prosthesis valve dehiscence is one of the most serious complications prosthetic valves. Despite improvements in medical and surgical treatments, prosthesis has high mortality. Due to fatality rates, early diagnosis treatment these patients required. In this case report, we presented a patient with severe mitral deficiency acute heart failure following mechanical secondary culture-negative endoc...

BACKGROUND Postprocedural aortic regurgitations following transcatheter aortic valve implantation (TAVI) procedures remain an issue. Benefit of oversizing strategies to prevent them isn't well established. We compared different level of oversizing in our cohort of consecutive patients to address if severe oversizing compared to normal sizing had an impact on post-procedural outcomes. METHODS ...